Cancer Comorbidities: Clinical Impacts, Mechanistic Insights, and Management Strategies
Authors:
Open Access
- 4 February 2026
- journal article
- Published by Wiley in MedComm – Oncology
- Vol. 5 (1)
Abstract
Cancer patients often have comorbidities that complicate treatment and worsen outcomes. Despite ongoing discussions, the interactions between comorbidities and cancer remain insufficiently understood. In addition, a widely accepted consensus on the document, assessment, and management of these comorbidities has not yet been established. This review aims to systematically synthesize current knowledge and propose a comprehensive framework for addressing these gaps. It summarizes the epidemiology and analyzes the clinical impacts of comorbidities on cancer patients, emphasizing the critical role of effective management of cancer comorbidities. It further examines key management challenges, including gaps in mechanisms and clinical evidence, the lack of precise assessment tools, limited management frameworks, and underdeveloped multidisciplinary collaborations. To address the complex interactions between cancer and comorbidities, this review proposes the establishment of Oncology‐Comorbidity as a novel discipline and Oncology‐Comorbidity Interaction Pathology as a theoretical framework. The assistance of artificial intelligence and real‐world data, together with effective multidisciplinary collaborations, is emphasized as an essential management strategy. Comprehensive, patient‐centered Life‐Course Cohort Studies are identified as indispensable tools. Ultimately, this review aims to advance the understanding of cancer‐comorbidity interactions, provide a roadmap for optimizing comorbidities management, and offer an effective pathway to improve prognosis and quality of life for cancer patients.Keywords
Funding Information
- National Natural Science Foundation of China (82130080)
- National Natural Science Foundation of China (U24A20726)
This publication has 198 references indexed in Scilit:
- Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease MedicationsJAMA Network Open, 2024
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050JAMA Oncology, 2023
- Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019JAMA Oncology, 2021
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug ConjugatesJAMA Oncology, 2021
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017JAMA Oncology, 2019
- HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United StatesJAMA Oncology, 2019
- Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung CancerJAMA, 2019
- Relation Between Medicare Screening Reimbursement and Stage at Diagnosis for Older Patients With Colon CancerJAMA, 2006
- Prognostic Importance of Comorbidity in a Hospital-Based Cancer RegistryJAMA, 2004